

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (GH-171) ALNUCTAMAB  
 PRONUNCIATION al nuk' ta mab  
 THERAPEUTIC CLAIM Treatment of hematologic malignancies

CHEMICAL NAME

Immunoglobulin G1 [146-glutamic acid,212-glutamic acid,458-alanine,459-alanine,553-glycine,578-cysteine,590-tryptophan], anti-(human B-cell maturation antigen) (human monoclonal 83A10-42 VH-CH1 fragment) fusion protein with peptide (synthetic GGGGSGGGGS linker) fusion protein with immunoglobulin anti-(human CD3 antigen ε-chain) (human-Mus musculus monoclonal CH2527 heavy chain VL(λ)-CH1-CH2-CH3), (219→216''')-disulfide with immunoglobulin anti-(human B-cell maturation antigen) (human monoclonal 83A10-42 κ-chain [125-arginine,126-lysine]) and (444→232''')-disulfide with immunoglobulin anti-(human CD3 antigen ε-chain) (human-Mus musculus monoclonal CH2527 light chain VH-CL(κ)), (450→225'), (453→228'), (578→348')-tris(disulfide) with immunoglobulin G1 [146-glutamic acid,212-glutamic acid,233-alanine,234-alanine,328-glycine,348-cysteine,365-serine,367-alanine,406-valine] anti-(human B-cell maturation antigen) (human monoclonal 83A10-42 γ1-chain), (219'→216''') disulfide with human monoclonal 83A10-42 κ-chain [125-arginine,126-lysine]

STRUCTURAL FORMULA

Heavy chain (anti-CD269 antigen and anti-CD3e antigen) A arm

EVQLLES	GGG	LVQPGG	SLRL	SCAASG	FTF	DNAMGW	RQA	PGKGLE	WVSA	50				
ISGPGS	STYY	ADSVKGR	FTI	SRDNSK	N	NTLY	LQMNSL	RAED	TAVYYC	AKVL	100			
GWFDY	WGQGT	LVTVSS	ASTK	GPSVFP	LAPS	SKSTSG	GTAA	LGCLVE	DYFP	150				
EPVTVS	WN	ALTS	GVHTFP	AVLQSS	GLYS	LSSVVT	VPSS	SLGTQT	YICN	200				
VNHKPS	NTKV	DEKVEP	KSCD	GGGSGG	GGGS	QAVVTQ	EP	TVSPGG	TVTL	250				
TCGSST	GAVT	TSNYAN	VWVQE	KPGQAF	RGLI	GGTNKR	APGT	PARFSG	SLLG	300				
GKAAL	TL	SGA	QPEDEA	EYYC	ALWY	SNLW	VF	GGG	TKLTVLS	350				
PLAPSS	SKSTS	GGTAAL	GCLV	KDYFPE	PVTV	SWNSG	ALTSG	VHTFPA	VLQS	400				
SGLYSL	SSV	TVPSS	SLGTQ	TYICNV	NH	KP	SNTKVD	KKVE	PKSCDK	THTC	450			
PPCPAPE	E	AG	GPSVFL	FPPK	PKDTLM	ISRT	PEVTCV	VVDV	SHEDPE	VKFN	500			
WYVDG	VEVHN	AKTKPRE	E	EQY	N	STYRVV	SVL	TVLHQD	WLNG	KEYKCK	VSNK	550		
ALGAPI	E	KTI	SKAKGQ	PREP	QVYTL	P	PCRD	ELTKNQ	VSLW	CLVKG	F	PSD	600	
I	AVEWES	NGQ	PENNYK	T	TPP	VLDS	DGSFFL	YSKLT	V	DKSR	WQQGN	V	FSCS	650
VMHEAL	HNHY	TQKSL	SLSPG	K										671

Heavy chain (anti-CD269 antigen) B arm

EVQLLES	GGG	LVQPGG	SLRL	SCAASG	FTF	DNAMGW	RQA	PGKGLE	WVSA	50'			
ISGPGS	STYY	ADSVKGR	FTI	SRDNSK	N	NTLY	LQMNSL	RAED	TAVYYC	AKVL	100'		
GWFDY	WGQGT	LVTVSS	ASTK	GPSVFP	LAPS	SKSTSG	GTAA	LGCLVE	DYFP	150'			
EPVTVS	WN	ALTS	GVHTFP	AVLQSS	GLYS	LSSVVT	VPSS	SLGTQT	YICN	200'			
VNHKPS	NTKV	DEKVEP	KSCD	KTHTCP	PCPA	PEAAGG	PSVF	LFPPK	PKDTL	250'			
MISRT	PEVTC	VVDV	SHEDP	E	VKFNWY	V	DG	VEVHNA	TKTP	REEQYN	STYR	300'	
VVSVL	TVLHQ	DWLNG	KEYKC	KVSNK	ALGAP	IEKT	ISKAKG	QPREP	QVCTL	350'			
PPSRDE	LTKN	QVSL	SCAVKG	FYP	SDIA	VEW	ESNGQ	PENNY	K	TTPV	LDSD	400'	
GSFFLV	SKLT	V	DKSRW	Q	QGN	V	FSCSV	M	HEA	LHNHY	TQKSL	SLSPGK	446'

Light chain (anti-CD3e antigen) A arm

EVQLLES	GGG	LVQPGG	SLRL	SCAASG	FTF	TYAMNW	RQA	PGKGLE	WVSR	50"	
IRSKYNN	YAT	YYADSV	KGRF	TISR	DDSKNT	LYLQMN	SLRA	EDTAVY	Y	CVR	100"
HGNFNG	SYVS	W	FAYWGQ	GT	VTVSSAS	VAA	PSVFI	FPPSD	EQLKSG	TASV	150"

VCLLNNFYPR	EAKVQWKVDN	ALQSGNSQES	VTEQDSKDST	YLSSTLTLS	200"
KADYEKHKVY	ACEVTHQGLS	SPVTKSFNRR	EC		232"

Light chain (anti-CD269 antigen) A arm

EIVLTQSPGT	LSLSPGERAT	LSCRASQSVS	DEYLSWYQQK	PGQAPRLLIH	50"
SASTRATGIP	DRFSGSGSGT	DFTLAISRLE	PEDFAVYYCQ	QYGYPPDFTF	100"
GQGTKVEIKR	TVAAPSVFIF	PPSDRKLKSG	TASVVCLLNN	FYPREAKVQW	150"
KVDNALQSGN	SQESVTEQDS	KDSTYSLSST	LTLISKADYEK	HKVYACEVTH	200"
QGLSSPVTKS	FNRGEC				216"

Light chain (anti-CD269 antigen) B arm

EIVLTQSPGT	LSLSPGERAT	LSCRASQSVS	DEYLSWYQQK	PGQAPRLLIH	50"
SASTRATGIP	DRFSGSGSGT	DFTLAISRLE	PEDFAVYYCQ	QYGYPPDFTF	100"
GQGTKVEIKR	TVAAPSVFIF	PPSDRKLKSG	TASVVCLLNN	FYPREAKVQW	150"
KVDNALQSGN	SQESVTEQDS	KDSTYSLSST	LTLISKADYEK	HKVYACEVTH	200"
QGLSSPVTKS	FNRGEC				216"

Disulfide bridges

22-96	22'-96'	22"-98"	23'''-89'''	23'''-89'''	136'''-196'''	136'''-196'''	143-199
143'-199'	152"-212"	252-320	260'-320'	219-216'''	219'-216'''	366'-424'	368-424
444-232"	450-225'	453-228'	485-545	578-348'	591 - 649		

Glycosylation sites (N)

Asn-296' Asn-521

MOLECULAR FORMULA  $C_{852}H_{13150}N_{2288}O_{2687}S_{54}$  (non glycosylated)

MOLECULAR WEIGHT 192.4 kDa (non glycosylated)

TRADEMARK None as yet

SPONSOR Celgene International II Sarl c/o Celgene Corporation

CODE DESIGNATIONS CC-93269, EM901, BMS-986349

CAS REGISTRY NUMBER 2296827-07-9

UNII 7OSV6M6T4D

WHO NUMBER 11457

gbk